GSK (GSK) issues statement Zantac (ranitidine) litigation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Why GSK and Sanofi Shares are Trading Sharply Lower This Week
August 11, 2022 8:44 AM EDTShares of GSK (NYSE: GSK), formerly GlaxoSmithKline, are down over 8% in premarket Thursday amid mounting concerns about the recalled drug Zantac.
The company is facing lawsuits as it allegedly failed to warn users about the over-the-counter products health risks. Zantac was a popular drug that was recalled since it... More
